骨髓增生异常综合征/骨髓增殖性肿瘤的治疗进展

曹蓝; 洪鸣

doi:10.13201/j.issn.1004-2806.2021.09.017

骨髓增生异常综合征/骨髓增殖性肿瘤的治疗进展

曹蓝,
洪鸣^,

- 南京医科大学第一附属医院江苏省人民医院血液科(南京, 210029)

详细信息

通讯作者: 洪鸣,E-mail:minniehm122@163.com

中图分类号: R733.3

收稿日期: 2020-12-28

Treatment advances in myelodysplastic/myeloproliferative neoplasms

CAO Lan,
HONG Ming^,

More Information

Corresponding author: HONG Ming, E-mail: minniehm122@163.com

Received Date: 28 December 2020

摘要

- 骨髓增生异常综合征/骨髓增殖性肿瘤 /
- 治疗 /
- 最新进展
- myelodysplastic/myeloproliferative neoplasms /
- treatment /
- advances

HTML全文

参考文献(35)

[1]	Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[2]	慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版)[J].中华血液学杂志,2021,42(1):5-9.
[3]	Hunter A,Al Ali N,Mai A,et al.Leukocytosis is associated with end organ damage in chronic myelomonocytic leukemia(CMML)and can be mitigated with cytoreductive therapy[C].Blood,2018,132:3109.
[4]	Xicoy B,Germing U,Jimenez MJ,et al.Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia[J].Eur J Haematol,2016,97(1):33-38.
[5]	Antelo G,Mangaonkar AA,Coltro G,et al.Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis(MDS/MPN-RS-T)[J].Br J Haematol,2020,189(3):e104-e108.
[6]	Chan O,Komrokji RS.Luspatercept in the treatment of lower-risk myelodysplastic syndromes[J].Future Oncol,2021,17(12):1473-1481.
[7]	Kubasch AS,Fenaux P,Platzbecker U,et al.Development of luspatercept to treat ineffective erythropoiesis[J].Blood Adv,2021,5(5):1565-1575.
[8]	Komrokji R,Garcia-Manero G,Ades L,et al.Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes:a phase 2,dose-ranging trial[J].Lancet Haematol,2018,5(2):e63-e72.
[9]	侯明.免疫性血小板减少症的治疗进展[J].临床血液学杂志,2020,33(1):6-9.
[10]	Ramadan H,Duong VH,Al Ali N,et al.Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia(CMML):A Cautionary Tale[J].Clin Lymphoma Myeloma Leuk,2016,16 Suppl:S64-S66.
[11]	Komrokji RS,List AF.Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q)myelodysplastic syndromes[J].Ann Oncol,2016,27(1):62-68.
[12]	Sekeres MA,Othus M,List AF,et al.Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia:North American Intergroup Study SWOG S1117[J].J Clin Oncol,2017,35(24):2745-2753.
[13]	Nicolosi M,Mudireddy M,Vallapureddy R,et al.Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis(MDS/MPN-RS-T)[J].Am J Hematol,2018,93(1):E27-E30.
[14]	Merlevede J,Droin N,Qin T,et al.Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents[J].Nat Commun,2016,7:10767.
[15]	Hunter AM,Al Ali N,Sallman DA,et al.WHO-defined Chronic Myelomonocytic Leukemia-2(CMML-2) patients rapidly progress to AML suggesting this entity represents a transitory clinical state[C].Blood,2019,134(Supplement_1):1717.
[16]	Xu R,Li M,Wu P,et al.Hypomethylating agents in the treatment of chronic myelomonocytic leukemia:a meta-analysis and systematic review[J].Hematology,2021,26(1):312-320.
[17]	Coston T,Pophali P,Vallapureddy R,et al.Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia;a single institutional study of 121 patients[J].Am J Hematol,2019,94(7):767-779.
[18]	Garcia-Manero G,Roboz G,Walsh K,et al.Guadecitabine(SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes:phase 2 results from a multicentre,open-label,randomised,phase 1/2 trial[J].Lancet Haematol,2019,6(6):e317-e327.
[19]	Dhillon S.Decitabine/Cedazuridine:First Approval[J].Drugs,2020,80(13):1373-1378.
[20]	Garcia-Manero G,Griffiths EA,Steensma DP,et al.Oral cedazuridine/decitabine for MDS and CMML:a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study[J].Blood,2020,136(6):674-683.
[21]	Savona MR,Kolibaba K,Conkling P,et al.Extended dosing with CC-486(oral azacitidine)in patients with myeloid malignancies[J].Am J Hematol,2018,93(10):1199-1206.
[22]	Chan O,Renneville A,Padron E.Chronic myelomonocytic leukemia diagnosis and management[J].Leukemia,2021,35(6):1552-1562.
[23]	刘凤琪,梁子杨,王荷花,等.地西他滨联合化学治疗对中高危慢性粒单核细胞白血病的疗效分析[J].新医学,2019,50(4):244-248.
[24]	肖志坚.骨髓增生异常综合征/骨髓增殖性肿瘤的诊断和治疗[J].中国实用内科杂志,2018,38(2):93-97.
[25]	胡文青.慢性粒单核细胞白血病诊治进展[J].临床血液学杂志,2019,32(3):242-246.
[26]	Patnaik MM,Tefferi A.Chronic Myelomonocytic leukemia:2020 update on diagnosis,risk stratification and management[J].Am J Hematol,2020,95(1):97-115.
[27]	Symeonidis A,van Biezen A,de Wreede L,et al.Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia.A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation[J].Br J Haematol,2015,171(2):239-246.
[28]	Kongtim P,Popat U,Jimenez A,et al.Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia[J].Biol Blood Marrow Transplant,2016,22(1):47-53.
[29]	李雪锴,徐杨,吴德沛.地西他滨联合异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床研究[J].临床血液学杂志,2021,34(3):182-187.
[30]	Radujkovic A,Hegenbart U,Müller-Tidow C,et al.High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia:a single-center experience[J].Ann Hematol,2020,99(4):855-866.
[31]	Assi R,Kantarjian HM,Garcia-Manero G,et al.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms[J].Am J Hematol,2018,93(2):277-285.
[32]	Azizi A,Ediriwickrema A,Dutta R,et al.Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes:a retrospective evaluation of a real-world experience[J].Leuk Lymphoma,2020,61(11):2700-2707.
[33]	Navada SC,Garcia-Manero G,OdchimarReissig R,et al.Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia:Results of a phase 1 study[J].Leuk Res,2020,94:106369.
[34]	Patnaik MM,Sallman DA,Mangaonkar AA,et al.Phase 1 study of lenzilumab,a recombinant anti-human GM-CSF antibody,for chronic myelomonocytic leukemia[J].Blood,2020,136(7):909-913.
[35]	Patnaik MM,Ali H,Gupta V,et al.Results from ongoing phase 1/2 clinical trial of tagraxofusp(SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia(CMML)[J].J Clin Oncol,2019,37(15_suppl):7059.